PACT Pharma

PACT Pharma is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2016.

The company focuses on developing personalized cancer therapies, specifically through its Personalized Adoptive Cell Therapy (PACT) approach. PACT Pharma specializes in creating individualized immunotherapies that utilize the patient's immune system to target solid tumors, which have historically been challenging to treat. The company employs a proprietary technology platform that includes neoantigen identification, personalized T-cell receptor (TCR) engineering, and non-viral delivery methods. Its lead product, NeoTCR-P1, is a fully personalized TCR-T cell therapy designed to treat solid tumors by reprogramming the immune system to recognize and attack cancer cells. PACT Pharma's vision emphasizes making personalized treatment accessible to all cancer patients, regardless of their background.